Atezolizumab is a monoclonal antibody used as an immunotherapy treatment for various types of cancer. It works by blocking the interaction between the protein PD-L1 and its receptors, PD-1 and B7.1, on immune cells, which essentially allows the immune system to recognize and attack cancer cells more effectively.
